Type
|
Public |
---|---|
Traded as | NASDAQ: NEO |
Industry | Biotechnology, Health care |
Founded | 2002 |
Headquarters | Fort Myers, Florida, United States |
Area served
|
Worldwide |
Key people
|
Douglas M. VanOort (Chairman and CEO) |
Number of employees
|
1000 (2017) |
Website | neogenomics |
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is a high-complexity CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.
NeoGenomics first received state and national-level laboratory certifications in 2002. 3 years later in 2005, the company developed a technical-only service model using FISH.
In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.
In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc. , a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.
In November 2017, NeoGenomics will establish their first headquarters outside the United States in Rolle, Switzerland.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-02 | Future report Set alerts | |
Q2 2022 | 2022-08-09 | -0.16 | -0.16 |
Q1 2022 | 2022-04-27 | -0.20 | -0.20 |
Q4 2021 | 2022-02-23 | -0.14 | -0.14 |
Q3 2021 | 2021-11-04 | -0.08 | -0.08 |
Q2 2021 | 2021-08-06 | -0.01 | -0.01 |
Q1 2021 | 2021-05-05 | -0.04 | -0.04 |
Q4 2020 | 2021-02-24 | 0.14 | 0.14 |
Q3 2020 | 2020-10-27 | 0.00 | 0.00 |
Q2 2020 | 2020-07-28 | -0.04 | -0.06 |
2016-07-09 | Reiterated Rating | Craig Hallum | Buy | |
2016-07-08 | Reiterated Rating | BTIG Research | Buy | $10.00 |
2016-05-11 | Initiated Coverage | Roth Capital | Buy | $10.00 |
2016-04-28 | Boost Price Target | Benchmark Co. | Buy | $8.00 to $9.00 |
2016-03-11 | Initiated Coverage | Benchmark Co. | Buy | $8.00 |
2016-03-03 | Reiterated Rating | BTIG Research | Buy | $9.00 |
2016-01-07 | Initiated Coverage | Janney Montgomery Scott | Buy | $11.00 |
2015-11-02 | Boost Price Target | Craig Hallum | Buy | $8.00 to $10.00 |
2015-11-01 | Reiterated Rating | BTIG Research | Buy | $9.00 |
2015-10-26 | Reiterated Rating | William Blair | Buy | |
2015-10-21 | Reiterated Rating | BTIG Research | Buy | $7.00 |
2015-09-28 | Reiterated Rating | BTIG Research | Buy | $8.00 |
2015-09-06 | Reiterated Rating | William Blair | Outperform | |
2015-09-03 | Reiterated Rating | Roth Capital | Buy | |
2015-07-24 | Reiterated Rating | BTIG Research | Buy | $8.00 |
2015-07-13 | Boost Price Target | Roth Capital | $7.00 to $7.50 | |
2015-07-12 | Reiterated Rating | Roth Capital | Buy | $7.00 to $7.50 |
2015-07-09 | Reiterated Rating | BTIG Research | Buy | $7.00 |
2015-07-06 | Reiterated Rating | Roth Capital | Buy | $7.00 to $7.00 |
2015-06-23 | Initiated Coverage | BTIG Research | Buy | $7.00 |
2015-06-22 | Initiated Coverage | BTIG Research | Buy | $7.00 |
2015-04-13 | Set Price Target | Roth Capital | Buy | $7.00 |
2014-05-14 | Initiated Coverage | Dawson James | Buy | $6.00 |
2014-05-12 | Initiated Coverage | Longbow Research | Buy | $6.00 |
2014-05-12 | Initiated Coverage | Roth Capital | Buy | $6.00 |
2014-02-14 | Initiated Coverage | Stephens | Overweight | $6.00 |
2014-01-08 | Initiated Coverage | William Blair | Outperform | |
2013-10-02 | Boost Price Target | Societe Generale | Hold | €50.00 to €54.00 |
2013-04-25 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
2013-02-14 | Reiterated | Ladenburg Thalmann | Buy | $3.50 to $3.75 |
2016-07-09 | Reiterated Rating | Craig Hallum | Buy | |
2016-07-08 | Reiterated Rating | BTIG Research | Buy | $10.00 |
2016-05-11 | Initiated Coverage | Roth Capital | Buy | $10.00 |
2016-04-28 | Boost Price Target | Benchmark Co. | Buy | $8.00 to $9.00 |
2016-03-11 | Initiated Coverage | Benchmark Co. | Buy | $8.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NEO 196 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 21.11M |
Vanguard Group, Inc | 13.17M |
BROWN ADVISORY INC | 6.18M |
HENDERSON GROUP PLC | 5.96M |
STATE STREET CORP | 4.22M |
GOLDMAN SACHS GROUP INC | 3.42M |
WELLINGTON MANAGEMENT CO LLP | 3.21M |
First Light Asset Management, LLC | 2.72M |
GEODE CAPITAL MANAGEMENT, LLC | 2.35M |
SCHRODER INVESTMENT MANAGEMENT GROUP | 2.30M |
EMERALD ADVISERS INC/PA | 2.14M |
FEDERATED INVESTORS INC /PA/ | 2.07M |
MACQUARIE GROUP LTD | 1.92M |
BlackRock Fund Advisors | 1.72M |
JANUS CAPITAL MANAGEMENT LLC | 1.68M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
KINDERHOOK PARTNERS, LP | 9.66% (4848334) | ACPW / NEO / PLPM / |
VAN OORT DOUGLAS M Chairman and CEO | 3.74% (1875000) | NEO / |
DENT MICHAEL T | 2.76% (1384150) | NEO / |
HIPP RAYMOND R | 0.54% (272016) | NEO / |
JONES STEVEN C Executive VP of Finance | 0.45% (226251) | NEO / |
CARDOZA GEORGE CFO | 0.44% (221089) | NEO / |
Robison William J | 0.37% (183348) | MWIV / NEO / |
Johnson Kevin C | 0.26% (128309) | NEO / |
HOREL ROBERT H. Vice President andGM PathLogic | 0.10% (51218) | NEO / |
ALBITAR MAHER Chief Medical Officer | 0.10% (48492) | NEO / |
HANNAH ALISON L. | 0.09% (45449) | NEO / |
BRODIE STEVEN G. Chief Scientific Officer | 0.07% (32619) | NEO / |
TETRAULT LYNN A. | 0.04% (21782) | NEO / |
CROWTHER BRUCE K | 0.03% (17202) | NEO / WTFC / |
GASPARINI ROBERT P Chief Science Officer | 0.02% (8439) | NEO / |
SHOVLIN ROBERT J. Chief Operating Officer | 0.01% (6550) | NEO / |
ROSS STEVEN A CIO | 0.01% (4500) | NEO / |